HER2 Peptide Vaccine Fails to Prevent Recurrence

cp418

http://www.oncologynurseadvisor.com/daily-oncology...

HER2 Peptide Vaccine Fails to Prevent Breast Cancer Recurrence

SpecialK

This trial was actually in conjunction with another Her2+ recurrence prevention vaccine - GP2. Participants were sorted into either the AE37 or GP2 arm dependent on histological tissue typing, like is done for organ transplant. I am enrolled in this trial, in Phase II, and was sorted to the GP2 arm, and I have completed my injections and boosters. I am now followed twice a year by phone, supplementing with labs and MO notes from my own center. I have concerns about whether the trial will be able to continue on to Phase III now that this news has come out about the ineffectiveness of the AE37 arm, particularly in light of the very good news about the effectiveness of the GP2 vaccine but the legal complications for the GP2 arm between the pharma companies and the original vaccine innovator, Dr. George Peoples. I am wondering if this less than stellar news about AE37, combined with the legal wrangling and funding issues with GP2, will end up dooming this trial altogether.